United States CRISPR Gene Editing Market is expected to reach US$ 12.78 billion by 2033 | Major key players - Thermo Fisher Scientific Inc., Lonza Bioscience, QIAGEN.

Market Size and Growth:

The Global CRISPR Gene Editing Market size reached US$ 4.21 Billion in 2023 with a rise of US$ 4.67 Billion in 2024 and is expected to reach US$ 12.78 Billion by 2033, growing at a CAGR of 11.9% during the forecast period 2025-2033. The Market is growing due to increasing adoption of gene therapies, rising prevalence of genetic disorders, and advances in biotechnology enabling precise and cost-effective genome editing.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://datamintelligence.com/download-sample/crispr-gene-editing-market?sz

The CRISPR Gene Editing Market involves the development and commercialization of technologies using CRISPR-Cas systems to precisely modify genes in organisms. It encompasses applications in therapeutics, agriculture, and biotechnology, enabling treatment of genetic disorders, crop improvement, and research advancements. Market growth is driven by increasing investment in gene therapies, demand for precision medicine, and innovations in genome engineering.

Industry Recent Developments:

United States:

✅ The U.S. continues to lead in CRISPR gene editing adoption with strong government initiatives and regulatory support enabling advancements in gene therapies and agricultural applications. Major biotechnology and pharmaceutical firms are advancing clinical trials and commercialization efforts. (reported October 2025)

✅ Artificial Intelligence integration is accelerating CRISPR gene editing by improving precision, efficiency, and safety through predictive algorithms that optimize guide RNA/DNA sequences and reduce off-target effects. AI-driven approaches are becoming standard tools in clinical trials. (reported July 2025)

✅ Expanded agricultural CRISPR applications in U.S. are encouraged by government support, promoting commercialization of genome-edited crops which enhances product traits such as disease resistance and yield. The U.S. FDA approvals for novel CRISPR-based therapies support market growth. (reported May 2025)

Japan:

✅ Researchers in Japan developed a genome editing method using CRISPR-Cas9 to partially inhibit gene function enabling precision breeding and improved crop resilience, without full gene deactivation. This was reported in March 2025 but has continued to influence market direction in latest months.

✅ In June 2025, Mie University researchers successfully used CRISPR-Cas9 to remove an extra chromosome in Down syndrome cells, restoring normal cell function, marking a breakthrough in genetic therapies.

✅ Japan's genome editing market is expecting rapid growth driven by government biotechnology investments, clinical trials expansion, and public-private collaborations, positioning Japan as a global leader in CRISPR technology adoption across medical and agricultural sectors. (reported October 2025)

Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/crispr-gene-editing-market?sz

FDA Approvals & Clinical Milestones:

CasgevyTM (exa-cel): Developed by Vertex Pharmaceuticals and CRISPR Therapeutics, Casgevy is the first CRISPR-based gene-editing therapy approved by the FDA. It targets transfusion-dependent beta-thalassemia and sickle cell disease by editing the BCL11A gene to reactivate fetal hemoglobin production.

Personalized CRISPR Therapy: In May 2025, the FDA approved a personalized CRISPR therapy for a critically ill infant named K.J., marking a significant step in individualized gene-editing treatments.

Urea Cycle Disorders: At the ESMO Congress in October 2025, researchers announced plans to seek FDA approval for a CRISPR-based trial targeting seven urea cycle disorders, highlighting the expanding scope of CRISPR applications.

Mergers & Acquisitions:

Eli Lilly & Verve Therapeutics: In June 2025, Eli Lilly announced the acquisition of Verve Therapeutics, a CRISPR-based gene-editing firm, for up to $1.3 billion. This strategic move aims to bolster Lilly's cardiovascular pipeline, particularly targeting the PCSK9 gene associated with high cholesterol.

AstraZeneca & Algen Biotechnologies: AstraZeneca entered into a $555 million agreement with Algen Biotechnologies, granting AstraZeneca exclusive rights to develop and commercialize therapies using Algen's CRISPR gene-editing technology.

Regulatory Landscape:

Global Developments: Countries are evaluating the regulation of gene-editing technologies, with some adopting more enabling rules for products resulting from the latest breeding methods, while maintaining high standards of food production.

UK Approval: In January 2025, the UK's National Health Service approved exagamglogene autotemcel (exa-cel), a CRISPR-based gene therapy for sickle cell disease, for use in England. This treatment offers a potential cure for patients without a matched donor for stem cell transplantation.

Major Key Players:

Thermo Fisher Scientific Inc.
New England Biolabs
Lonza Bioscience
Merck
Integrated DNA Technologies, Inc.
Synthego
GenScript
Takara Bio Inc.
QIAGEN
Agilent Technologies, Inc.

Segments Covered in the CRISPR Gene Editing Market:

By-Product: Kits and Reagents, Instruments.

By Gene Editing Modality: Ex-Vivo Editing and In-Vivo Editing.

By Technology: CRISPR/Cas9 Technology, CRISPR/Cas12 Technology, CRISPR/Cas13 Technology, Base Editing, Prime Editing, Epigenetic Editing and Others.

By End User: Academic and Research Institutes, Biotechnology and Pharmaceutical Companies, Agricultural and Livestock Industry, Hospitals and Clinics, Contract Research Organizations (CROs) and Others.

Regional Analysis:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Looking For Full Report? Get it Here: https://www.datamintelligence.com/buy-now-page?report=crispr-gene-editing-market

Chapter Outline

⏩ Market Overview: It contains five chapters, as well as information about the research scope, major manufacturers covered, market segments, CRISPR Gene Editing market segments, study objectives, and years considered.

⏩ Market Landscape: The competition in the Global CRISPR Gene Editing Market is evaluated here in terms of value, turnover, revenues, and market share by organization, as well as market rate, competitive landscape, and recent developments, transaction, growth, sale, and market shares of top companies.

⏩ Companies Profiles: The Global CRISPR Gene Editing market's leading players are studied based on sales, main products, gross profit margin, revenue, price, and growth production.

⏩ Market Outlook by Region: The report goes through gross margin, sales, income, supply, market share, CAGR, and market size by region in this segment. North America, Europe, Asia Pacific, Middle East & Africa, and South America are among the regions and countries studied in depth in this study.

⏩ Market Segments: It contains the deep research study which interprets how different end-user/application/type segments contribute to the CRISPR Gene Editing Market.

⏩ Market Forecast: Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

⏩ Research Findings: This section of the report showcases the findings and analysis of the report.

⏩ Conclusion: This portion of the report is the last section of the report where the conclusion of the research study is provided.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

People Also Ask:

◆ How big is the CRISPR Gene Editing Market in 2025?
◆ What is the projected growth rate of the CRISPR Gene Editing Market through 2033?
◆ Who are the key players in the CRISPR Gene Editing Market?
◆ Which region is expected to dominate the industry during the forecast period?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.